KPCB PBD Associates, LLC - Jul 13, 2023 Form 3 Insider Report for Sagimet Biosciences Inc. (SGMT)

Role: 10%+ Owner
Signature: KPCB PBD Associates, LLC, By: /s/ Susan Biglieri, CFO
Stock symbol: SGMT
Transactions as of: Jul 13, 2023
Transactions value $: $0
Form type: 3
Date filed: 7/13/2023, 09:25 PM
Next filing: Jul 20, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	SGMT	Common Stock						38.8K	Jul 13, 2023	See footnote	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Date	Underlying Class	Amount	Ownership	Footnotes
holding	SGMT	Series A Preferred Stock	Jul 13, 2023	Common Stock	6.78K	See footnote	F1, F2
holding	SGMT	Series B Preferred Stock	Jul 13, 2023	Common Stock	6.21K	See footnote	F1, F2
holding	SGMT	Series B-1 Preferred Stock	Jul 13, 2023	Common Stock	108K	See footnote	F1, F2
holding	SGMT	Series C Preferred Stock	Jul 13, 2023	Common Stock	108K	See footnote	F1, F2
holding	SGMT	Series D Preferred Stock	Jul 13, 2023	Common Stock	76.8K	See footnote	F1, F2
holding	SGMT	Series E Preferred Stock	Jul 13, 2023	Common Stock	1.3M	See footnote	F1, F2
holding	SGMT	Series F Preferred Stock	Jul 13, 2023	Common Stock	257K	See footnote	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents shares held directly by KPCB Pandemic and Bio Defense Fund, LLC ("KPCB PBD"). The managing member of KPCB PBD is KPCB PBD Associates, LLC ("KPCB PBD Associates"). All securities are held for convenience in the name of "KPCB Holdings, Inc., as nominee". KPCB PBD Associates disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose.
F2	Each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock and Series F Preferred Stock (collectively, the "Preferred Stock") is convertible into Common Stock on a 79.4784-to-one basis (on an adjusted basis, after giving effect to the reverse stock split of the Common Stock effected by the Issuer on July 7, 2023) at the option of the holder, and will convert automatically upon closing of the Issuer's initial public offering into the number of shares shown in column 3. The Preferred Stock has no expiration date.

Content

Represents shares held directly by KPCB Pandemic and Bio Defense Fund, LLC ("KPCB PBD"). The managing member of KPCB PBD is KPCB PBD Associates, LLC ("KPCB PBD Associates"). All securities are held for convenience in the name of "KPCB Holdings, Inc., as nominee". KPCB PBD Associates disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose.

Each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock and Series F Preferred Stock (collectively, the "Preferred Stock") is convertible into Common Stock on a 79.4784-to-one basis (on an adjusted basis, after giving effect to the reverse stock split of the Common Stock effected by the Issuer on July 7, 2023) at the option of the holder, and will convert automatically upon closing of the Issuer's initial public offering into the number of shares shown in column 3. The Preferred Stock has no expiration date.